valproic acid has been researched along with DIPG Brain Tumors in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the efficacy and tolerability of valproic acid (VPA) and radiation, followed by VPA and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG)." | 9.34 | A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. ( Adesina, AM; Baxter, PA; Blaney, SM; Bowers, DC; Jo, E; McNall-Knapp, RY; Mo, Q; Murray, JC; Paulino, AC; Shah, S; Su, JM, 2020) |
| "Effective treatment of diffuse intrinsic pontine glioma (DIPG) remains a formidable challenge due to inadequate penetration of the blood-brain barrier (BBB) by systemically administered chemotherapies." | 5.62 | Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy. ( Bienemann, A; Collins, P; Gill, S; Hollingworth, M; Hyare, H; Shankar, A; Szychot, E; Walker, D, 2021) |
| "To study the efficacy and tolerability of valproic acid (VPA) and radiation, followed by VPA and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG)." | 5.34 | A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. ( Adesina, AM; Baxter, PA; Blaney, SM; Bowers, DC; Jo, E; McNall-Knapp, RY; Mo, Q; Murray, JC; Paulino, AC; Shah, S; Su, JM, 2020) |
| "Effective treatment of diffuse intrinsic pontine glioma (DIPG) remains a formidable challenge due to inadequate penetration of the blood-brain barrier (BBB) by systemically administered chemotherapies." | 1.62 | Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy. ( Bienemann, A; Collins, P; Gill, S; Hollingworth, M; Hyare, H; Shankar, A; Szychot, E; Walker, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, JM | 1 |
| Murray, JC | 1 |
| McNall-Knapp, RY | 1 |
| Bowers, DC | 1 |
| Shah, S | 1 |
| Adesina, AM | 1 |
| Paulino, AC | 1 |
| Jo, E | 1 |
| Mo, Q | 1 |
| Baxter, PA | 1 |
| Blaney, SM | 1 |
| Szychot, E | 1 |
| Walker, D | 1 |
| Collins, P | 1 |
| Hyare, H | 1 |
| Shankar, A | 1 |
| Bienemann, A | 1 |
| Hollingworth, M | 1 |
| Gill, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas[NCT00879437] | Phase 2 | 38 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare 1-year EFS for this trial versus historical series (ACNS0126 for high-grade gliomas; CCG-9941 for DIPG) (NCT00879437)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 12 |
| High-grade Gliomas | 24 |
complete response defined as complete disappearance of all measurable lesions,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High-grade Gliomas | 1 |
estimate the median event free survival of patients receiving protocol therapy (NCT00879437)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 7.8 |
| High-grade Gliomas | 9.1 |
median OS of patients receiving protocol therapy (NCT00879437)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 10.3 |
| High-grade Gliomas | 12.1 |
partial response defined as 51% to 99% reduction in tumor size,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Diffuse Intrinsic Pontine Glioma | 8 |
partial response defined as 51% to 99% reduction in tumor size,determined using WHO bi-dimensional criteria (product of the greatest tumor diameter and its perpendicular diameter) (NCT00879437)
Timeframe: up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High-grade Gliomas | 5 |
Document frequency of grade 2 hypertension, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 8 |
document frequency of grade 2 cystitis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 abdominal pain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment, week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 abdominal pain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 anorexia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 AST elevation, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 cough, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 fatigue, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 or higher fatigue, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 7 |
document frequency of grade 2 hypoalbuminemia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 2 hypoglycemia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 hypoglycemia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 intratumoral/intracranial hemorrhage, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 ocular keratitis, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 pancreatitis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 proteinuria, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 2 somnolence, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 somnolence, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 2 weight gain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 4 |
document frequency of 2 weight gain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 cellulitis, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 dehydration, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
Document frequency of grade 3 fatigue, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 hypertension, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 4 |
document frequency of grade 3 leukopenia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 lipase and amylase elevation, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 lymphopenia, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 5 |
document frequency of grade 3 lymphopenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 neutropenia, graded by CTCAE v3.0, during concurrent valproic acid and radiation treatment for the first 10 weeks (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 neutropenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
Document frequency of grade 3 somonolence, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 subacute bone infarction, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 thrombocytopenia, graded according to CTCAE v3.0, during concurrent valproic acid and radiation treatment for week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 3 thrombocytopenia, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 3 |
document frequency of grade 3 weight gain, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment during week 1-10 (NCT00879437)
Timeframe: first 10 weeks of study
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
Document frequency of grade 3 weight gain, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 2 |
document frequency of grade 4 deep vein thrombosis, pulmonary embolism, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 4 radiation necrosis, assessed by CTCAE v3.0, during concurrent valproic acid and radiation treatment from week 1-10 (NCT00879437)
Timeframe: first 10 weeks of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
document frequency of grade 2 urinary tract infection, assessed by CTCAE v3.0, during maintenance therapy of valproic acid and bevacizumab, from week 11 to up to 24 months (NCT00879437)
Timeframe: from week 11 to up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| 38 Eligible Patients | 1 |
1 trial available for valproic acid and DIPG Brain Tumors
| Article | Year |
|---|---|
A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2020 |
1 other study available for valproic acid and DIPG Brain Tumors
| Article | Year |
|---|---|
Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy.
Topics: Antineoplastic Agents; Carboplatin; Child; Convection; Diffuse Intrinsic Pontine Glioma; Glioma; Hum | 2021 |